{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:22:46Z","timestamp":1791958966360,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jaad.2020.03.075","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T10:59:15Z","timestamp":1585738755000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis"],"prefix":"10.1016","volume":"83","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"F\u00f6lster-Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suephy C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Diepgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Elmets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2020.03.075_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjmed.2008.09.014","article-title":"Atopic dermatitis","volume":"122","author":"Wasserbauer","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2020.03.075_bib2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2020.03.075_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.03.075_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/all.12619","article-title":"Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities","volume":"70","author":"Mortz","year":"2015","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.075_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1398-9995.2012.02786.x","article-title":"Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort","volume":"67","author":"Ballardini","year":"2012","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.075_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamadermatol.2013.10271","article-title":"Persistence of mild to moderate atopic dermatitis","volume":"150","author":"Margolis","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.075_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000095289","article-title":"Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus","volume":"141","author":"Stuetz","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.075_bib8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2133.2008.08974.x","article-title":"Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis","volume":"160","author":"Undre","year":"2009","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.03.075_bib9","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1345\/aph.1M278","article-title":"Association between exposure to topical tacrolimus or pimecrolimus and cancers","volume":"43","author":"Hui","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.075_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.03.075_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2133.2011.10363.x","article-title":"Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors","volume":"165","author":"Tennis","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2 Suppl 2","key":"10.1016\/j.jaad.2020.03.075_bib12","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.jaad.2005.04.059","article-title":"The efficacy and safety of tacrolimus ointment: a\u00a0clinical review","volume":"53","author":"Beck","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.075_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1081-1206(10)61381-6","article-title":"The\u00a0black box warning for topical calcineurin inhibitors: looking outside the box","volume":"97","author":"Fonacier","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2020.03.075_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CLEP.S146442","article-title":"A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation-JOELLE study)","volume":"10","author":"Castellsague","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jaad.2020.03.075_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.jid.5700622","article-title":"Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis","volume":"127","author":"Arellano","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.03.075_bib16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1365-2133.2010.09887.x","article-title":"Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K","volume":"163","author":"Arana","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.075_bib17","unstructured":"Manthripragada A. Addendum: Update on calcineurin inhibitor pediatric literature review. May 10, 2011. Reference ID: 2944520. Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research."},{"key":"10.1016\/j.jaad.2020.03.075_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1081-1206(10)60632-1","article-title":"The association between allergies and cancer: what is currently known?","volume":"99","author":"Merrill","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2020.03.075_bib19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamadermatol.2014.4305","article-title":"Association between malignancy and topical use of pimecrolimus","volume":"151","author":"Margolis","year":"2015","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220304989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220304989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:11Z","timestamp":1759272971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220304989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0190962220304989"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.075","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}